{"id":"NCT02914184","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","officialTitle":"Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-27","primaryCompletion":"2018-06-27","completion":"2018-11-26","firstPosted":"2016-09-26","resultsPosted":"2019-10-14","lastUpdate":"2020-07-21"},"enrollment":1612,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Rotavirus","Rotavirus Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"HRV PCV-free liquid vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix","otherNames":[]}],"arms":[{"label":"Liq_A Group","type":"EXPERIMENTAL"},{"label":"Liq_B Group","type":"EXPERIMENTAL"},{"label":"Liq_C Group","type":"EXPERIMENTAL"},{"label":"Lyo Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the study.","primaryOutcome":{"measure":"Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C)","timeFrame":"At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)","effectByArm":[{"arm":"Liq_A Group","deltaMin":155.7,"sd":null},{"arm":"Liq_B Group","deltaMin":147.3,"sd":null},{"arm":"Liq_C Group","deltaMin":175.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":66,"countries":["United States","Costa Rica","Finland","Germany","Japan","South Korea","Spain","Taiwan"]},"refs":{"pmids":["32365189"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":400},"commonTop":["Irritability","Cough","Decreased appetite","Diarrhoea","Upper respiratory tract infection"]}}